Pharmacokinetic and pharmacodynamic properties of gliclazide were studied after an oral administration of gliclazide tablets in healthy volunteers. After an overnight fasting, gliclazide tablet was orally administered to 11 volunteers; Additional 10 volunteers were used as a control group (i.e., no gliclazide administration). Blood samples were collected, and the concentration determined for gliclazide and glucose up to 24 after the administration. Standard pharmacokinetic analysis was carried out for gliclazide. Pharmacodynamic activity of the drug was expressed by increase of glucose concentration ($Delta$PG), by area under the increase of glucose concentration-time curve ($AUC_{$Delta$PG}$</TEX>) or by the difference in increase of glucose concentration ($D_{$Delta$PG}$</TEX>) at each time between groups with and without gliclazide administration. Pharmacokinetic analysis revealed that $C_{max}, T_{max}$, CL/F (apparent clearance), V/F (apparent volume of distribution) and half-life of gliclazide were $4.69pm1.38 mg/L, 3.45pm1.11 h, 1.26pm0.35 L/h, 17.78pm5.27 L, and 9.99pm2.15 h$, respectively. When compared with the no drug administration group, gliclazide decreased significantly the $AUC_{$Delta$PG}$</TEX> s at 1, 1.5, 2, 2.5, 3 and 4 h (p＜0.05). The $Delta$PGs were positively correlated with $AUC_{gliclazide}$ at 1 and 1.5 h (p＜0.05), and the correlation coefficient was maximum at 1 h (r = 0.642) and gradually decreased at 4 h after the administration. The $AUC_{$Delta$PG}$</TEX>s were positively correlated with $AUC_{gliclazide}$ at 1, 2, 3 and 4 h (p＜0.05), and the maximum correlation coefficient was obtained at 2 h (r=0.642) after the administration. The $D_{$Delta$PG}$</TEX> reached the maximum at 1 h, remained constant from 1 h to 3 h, and decreased afterwards. Therefore, these observations indicated that maximum hypoglycemic effect of gliclazide was reached at approximately at 1.5 h after the administration and the effect decreased, probably because of the homeostasis mechanism, in health volunteers.